肺癌靶向治疗年度回顾.pptVIP

肺癌靶向治疗年度回顾;内 容;Overview of Molecular Pathways and Potential Targets in NSCLC;肺腺癌的靶向治疗;EGFR-TKIs vs. 化疗 （EGFR突变阳性）一线;Second-line EGFR-TKIs for Advanced NSCLC with EGFR Unselected;Second-line EGFR-TKIs for Advanced NSCLC with EGFR Wild-Type;新一代EGFT-TKIs Afatinib vs. 一线化疗（EGFR突变阳性肺腺癌）;Afatinib vs. 一线化疗（EGFR突变阳性肺腺癌）LUX-Lung 3;LUX-Lung 6：研究设计;Afatinib vs. 一线化疗（EGFR突变阳性肺腺癌） LUX-Lung 6;新一代EGFT-TKIs : Afatinib LUX-Lung 7 8: Going Head-to-Head;Irreversible Pan–Human EGFR-TKIs: Dacomitinib;Randomized Phase II StudyDacomitinib vs. Erlotinib in Advanced NSCLC;Dacomitinib vs. Erlotinib in Advanced NSCLCResults;Dacomitinib vs. Erlotinib in Advanced NSCLCAdverse Events;Phase III Study of 1st-line Dacomitinib vs. Gefitinib for Advanced NSCLC with EGFR Activating Mutation;以ALK为靶点的治疗;Phase III Study of 2nd-Line Crizotinib: PROFILE 1007;客观缓解率;PFS OS;无进展生存时间：亚组分析;克唑替尼250 mg BID 连续用药(n=100);正在研究的ALK抑制剂;以ROS RET为靶点的治疗;Crizotinib for ROS-Positive NSCLCn=40;RET融合基因的潜在治疗药物;以KRAS为靶点的治疗;MEK1/2抑制剂Selumetinib (SEL)Phase II 2nd-Line SEL/DTX vs. DTX in NSCLC with Mutant KRAS;研究结果：PFS OS;ASCO 2013：以KRAS为靶点的研究报告;以HSP90为靶点的治疗2nd-Generation Hsp90 Inhibitors Ganetespib ;Ganetespib in 2nd-line Treatment of NSCLCGALAXY-1;Ganetespib in 2nd-line Treatment of NSCLCGALAXY-1;以MET为靶点的治疗;MET Inhibitor;多靶点抑制剂--Nintedanib;Nintedanib vs. 化疗in 2nd-line treatment of NSCLC;LUME-LUNG 2: Nintedanib vs. PemetrexedResults;肺腺癌的新治疗靶点;内 容;肺鳞癌的分子改变;Novel Agents Targeting PI3K/ARK/RAS Signaling;内 容;Biomarkers France;A Multicenter Effort to Identify Driver Mutations and Employ Targeted Therapy in Patients with Lung Adenocarcinomas;问题 与 挑战;谢 谢！